A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia

Srdan Verstovsek,Stephane Courby,Martin Griesshammer,Ruben A. Mesa,Carrie Baker Brachmann,Jun Kawashima,Julia D. Maltzman,Lixin Shao,Yan Xin,Daniel Huang,Ashish Bajel

Leukemia Research（2017）

引用 30|浏览13

暂无评分

摘要

•Once-daily momelotinib 100mg or 200mg has limited activity in patients with PV/ET.•Predose momelotinib plasma levels were stable throughout the study.•Safety profile was comparable to results reported for momelotinib in myelofibrosis patients.

查看译文

关键词

Momelotinib,Polycythemia vera,Essential thrombocythemia,Phase 2 study

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要